文献速递临床试验与 GCP

持续缓解期类风湿关节炎患者逐步减量生物改善病情抗风湿药的有效性与安全性:非劣效随机对照单盲试验研究方案

Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial.
PubMed 文献 · Trials · 2022-07-27

本研究为24个月非劣效随机对照单盲试验,计划于2021年9月至2023年8月在本院开展,将患者按2:1随机分为维持组与逐渐减量组(每3个月减量50%或拉长注射间隔直至完全停药),主要结局为持续复发率,旨在为缓解期类风湿关节炎患者的减药策略提供参考。

要点

  • 研究比较维持治疗与逐渐减量生物改善病情抗风湿药两种策略。
  • 减量方案为每3个月减量50%或拉长注射间隔直至完全停药。
  • 主要结局为持续复发率,设计为非劣效随机对照单盲试验。

核心结论

  • 本研究可能为缓解期类风湿关节炎患者减药策略和治疗选择提供参考,以帮助提高治疗安全性并减轻经济负担。

研究设计与样本

  • 24个月非劣效随机对照单盲试验,计划于2021年9月至2023年8月在本院开展。
  • 患者按2:1随机分为维持组与逐渐减量组,减量组每3个月减量50%或拉长注射间隔直至完全停药。
  • 患者复发时恢复至最后一次有效剂量;若维持缓解,入组9个月后可停用生物改善病情抗风湿药。

关键数值与推荐

  • 主要结局为持续复发率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To compare the effects of two biologic disease-modifying antirheumatic drug (bDMARD) administration strategies on the maintenance effect and safety of patients with rheumatoid arthritis (RA) in remission, to analyze the effects of gradual drug reduction and dose maintenance treatment on clinical outcomes in patients who have achieved remission with different types of bDMARDs, to search and screen out people who may benefit from drug reduction strategies, and to provide references for drug reduction strategies and treatment options for patients with RA in remission, so as to help improve the safety of the treatment and reduce the economic burden. METHODS: The study will be a 24-month non-inferiority randomized, controlled, single-blind trial and is planned to be launched in our hospital from September 2021 to August 2023. Patients will be randomized in a ratio of 2:1 to two groups: maintenance or injection spacing by 50%/gradual reduction of dosage every 3 months up to complete stop. When the patient relapses, return to the last effective dose. If the remission can be maintained, the medication of bDMARDs can be stopped 9 months after enrollment. The primary outcome will be the persistent flare rate. DISCUSSION: Our study may provide a reference for the selection of drug reduction strategies and treatment options for patients with RA in remission, so as to help improve the safety of the treatment and reduce the economic burden. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100044751. Registered on 26 March 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lei S, Li Z, Zhang X, et al. Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial. Trials. 2022. PMID: 35897052. doi:10.1186/s13063-022-06543-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。